What Is New in CTCL—Pathogenesis, Diagnosis, and Treatments

Brittany O. Dulmage, Betty Y. Kong, Kassandra Holzem, Joan Guitart*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Purpose of Review: Cutaneous T cell lymphoma (CTCL) is a heterogeneous group of non-Hodgkin’s lymphoma primarily affecting the skin, of which mycosis fungoides (MF) and Sézary syndrome (SS) account for the majority of cases. The pathogenesis of CTCL is poorly understood with no strongly associated environmental or genetic risk factors identified to date. As such, the development of disease-specific therapies has been limited by a lack of understanding of potentially actionable targets. Moreover, the diagnosis of CTCL remains challenging with nonspecific diagnostic criteria, especially in early-stage disease. Recent Findings: The advent of high-throughput sequencing techniques and molecular modalities has provided significant insight into disease pathogenesis, diagnosis, and potential therapies. Summary: Here, we review the classic features of CTCL, focusing on MF/SS, and provide updates on our understanding of this disease.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalCurrent Dermatology Reports
Volume7
Issue number2
DOIs
StatePublished - Jun 1 2018

Keywords

  • Checkpoint inhibitor
  • Cutaneous T cell lymphoma
  • Monoclonal antibody
  • Mycosis fungoides
  • Sézary syndrome
  • T cell receptor

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'What Is New in CTCL—Pathogenesis, Diagnosis, and Treatments'. Together they form a unique fingerprint.

Cite this